ICCC Q4 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+52.1% YoY

Gross Profit

$3M36.5% margin

Operating Income

$621,3958.0% margin

Net Income

$514,5556.6% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+28.9%

Cash Flow

Operating Cash Flow

-$3,051

Free Cash Flow

-$199,267

Stock-Based Comp.

$68,863

Balance Sheet

Total Assets

$45M

Total Liabilities

$18M

Stockholders' Equity

$28M

Cash & Equivalents

$4M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$5M	+52.1%
Gross Profit	$3M	$1M	+125.1%
Operating Income	$621,395	-$1M	+162.0%
Net Income	$514,555	-$1M	+145.1%

Geographic Segments

UNITED STATES

$6M100%